美國Seracare傳染病陽性血清轉換盤（120種血清盤）

廣州健侖生物科技有限公司

SeraCare Life Sciences公司主要在美國、歐洲和亞洲提供促進人類和動物診斷和治療學的探索、開發(fā)和生產(chǎn)的產(chǎn)品和服務。其業(yè)務分為兩個部分：診斷和生物制藥產(chǎn)品和生物服務。診斷和生物制藥產(chǎn)品部門生產(chǎn)和銷售診斷和控制面板產(chǎn)品，用于測試傳染性疾病的臨床實驗室及員工培訓和能力測試。生物服務部門提供生物銀行、來樣加工和測試服務。

美國SeraCare收購BBI公司，即原BBI血清盤已經(jīng)改名為SeraCare血清盤。

其產(chǎn)品包括有：傳染病陽性質(zhì)控品、疾病標準品、細菌陽性質(zhì)控品、人血清白蛋白、人伽馬球蛋白、牛血清白蛋白、血清盤、人血漿、人血清。

SeraCare的血清盤包括：HIV-1轉化盤、HIV性能盤、HBV轉化盤、HBV性能盤、HCV轉化盤、HCV性能盤、弓形蟲性能盤、線性盤和質(zhì)控盤等等。

我司還提供其它進口或國產(chǎn)試劑盒：登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團菌、化妝品檢測、食品安全檢測等試劑盒以及日本生研細菌分型診斷血清、德國SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。

歡迎咨詢

歡迎咨詢2042552662

美國Seracare傳染病陽性血清轉換盤（120種血清盤）

美國Seracare

想了解更多的產(chǎn)品及服務請掃描下方二維碼：

【公司名稱】 廣州健侖生物科技有限公司

【市 場 部】    楊永漢

【】 

【騰訊Q Q】 2042552662

【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號二期2幢101-103室

來自CG公司(Complete genomics)、Reprogenetics公司以及紐約大學生殖中心(NYU Fertility Center)的科學家開發(fā)出一種新的“全基因組測序”的方法，或許可以解決這一難題。他們從剛剛接受體外受精的試管胚胎中提取5到10個細胞組織，進行掃描，分析其可能存在的不利突變。這項研究2月11日在線發(fā)表在Genome Research上。
首先，研究者從2個IVF胚胎中挑選的3個活體細胞組織進行基因測序以尋找新生突變，發(fā)現(xiàn)精子和卵子的突變并不*繼承父母雙親的基因。那些自發(fā)的突變常常會引起先天性混亂，例如自閉癥、癲癇以及一些嚴重的智力問題。
CG公司的*科學家Radoje Drmanac博士和這項研究、文章的共同作者Brock Peters則認為：由于每個個體基因引起的新生突變平均小于100個，而要檢出父母雙方的原始突變，這能夠?qū)е略S多類型的疾病，需要極低的錯誤率。
過去從胚胎的囊胚中提取5到10個細胞活體組織，在進行測序前，DNA先被擴增。由于缺乏復制的保真度，擴增過程將產(chǎn)生成千上萬個錯誤，其中很多錯誤將會導致連續(xù)的突變，并產(chǎn)生假陽性結果。現(xiàn)在的方法，是利用長片段的讀取技術，可以消除100,000個測序錯誤，若是用于臨床上，將會減少100個錯誤折疊。
根據(jù)文章所述，科學家能夠檢測出IVF胚胎中82%的新生突變。有意思的是，他們在一個胚胎中的蛋白編碼區(qū)域找不到任何突變，而來自同一夫婦的另一個胚胎則出現(xiàn)了2個編碼突變，分別是ZNF266和SLC26a10基因，這些基因的突變導致了很嚴重的疾病或遺傳缺陷。然而科學家目前還不清楚他們所觀察到的特殊突變是否會導致胎兒的其他健康風險。Drmanac教授和Peters教授補充道：現(xiàn)在zui大的問題是怎樣分析這些突變對醫(yī)學的影響，并基于這些結果做出何種決定。
此外，科學家認為全基因組測序技術(WGS)對試管嬰兒(IVF)的另一好處是可以用于難以獲得細胞的臨床應用，譬如腫瘤循環(huán)細胞及胎兒循環(huán)細胞。
隨著測序技術的發(fā)展，宏基因組學逐漸成為了新的熱門領域。宏基因組學主要是鑒定環(huán)境樣本中的所有微生物，理解它們各自所起的作用。這類研究比一般的基因組分析更需要計算機技術的幫助，因為宏基因組學研究的是不同基因組的混合物。

Scientists from Complete Genomics, Reprogenetics, and the NYU Fertility Center have developed a new "genome-wide sequencing" approach that may solve this problem. They extracted 5 to 10 cell tissues from in vitro fertilized test-tube embryos and scanned them for possible adverse mutations. The study was published online at Genome Research on February 11th.
First, the researchers performed genetic sequencing on three live cell tissues selected from two IVF embryos to search for new mutations. It was found that mutations in sperm and eggs did not compley inherit the genes of both parental parents. Those spontaneous mutations often cause congenital disorders such as autism, epilepsy, and some serious inlectual problems.
Dr. Radoje Drmanac, chief scientist of CG Corporation, and led the study, co-author Brock Peters, believes that because each individual gene causes fewer than 100 new mutations on average, it is necessary to detect the original mutations of both parents, which can lead to Many types of diseases require extremely low error rates.
In the past, 5 to 10 cells of living tissue were extracted from embryonic blastocysts and the DNA was first amplified before sequencing. Due to the lack of replication fidelity, the amplification process will generate thousands of errors, many of which will lead to continuous mutations and false positive results. The current method is to use long-range reading technology, which can eliminate 100,000 sequencing errors. If it is used clinically, it will reduce 100 misfoldings.
According to the article, scientists were able to detect 82% of newborn mutations in IVF embryos. Interestingly, they could not find any mutations in the protein coding region of one embryo, while two embryos from the same couple had two coding mutations, the ZNF266 and SLC26a10 genes, and the mutations in these genes caused serious mutations. The disease or genetic defect. However, scientists are still unclear whether the specific mutations they observe will cause other health risks to the fetus. Prof. Drmanac and Professor Peter added: The biggest question now is how to analyze the impact of these mutations on medicine, and based on these results What kind of decision.
In addition, scientists believe that another benefit of whole genome sequencing (WGS) for IVF is that it can be used in clinical applications where it is difficult to obtain cells, such as tumor circulating cells and fetal circulating cells.
With the development of sequencing technology, metagenomics has gradually become a new hot area. Metagenomics is mainly to identify all microorganisms in an environmental sample and understand their respective roles. This type of research requires more computer technology than generic genomics because metagenomics studies a mixture of different genomes.